BRPI1008566A8 - métodos e composições para o diagnóstico e tratamento de câncer - Google Patents

métodos e composições para o diagnóstico e tratamento de câncer

Info

Publication number: BRPI1008566A8
Authority: BR; Brazil
Prior art keywords: compositions; treatment; methods; cancer diagnosis; diagnosis
Prior art date: 2009-02-20

Application number

BRPI1008566A

Other languages

English (en)

Inventor

Koslowski Michael

Sahin Ugur

Türeci Özlem

Original Assignee

Ganymed Pharmaceuticals Ag

Univ Mainz Johannes Gutenberg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-20

Filing date

2010-02-18

Publication date

2018-01-02

2010-02-18 Application filed by Ganymed Pharmaceuticals Ag, Univ Mainz Johannes Gutenberg filed Critical Ganymed Pharmaceuticals Ag

2017-06-06 Publication of BRPI1008566A2 publication Critical patent/BRPI1008566A2/pt

2018-01-02 Publication of BRPI1008566A8 publication Critical patent/BRPI1008566A8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Pathology (AREA)
Hospice & Palliative Care (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BRPI1008566A 2009-02-20 2010-02-18 métodos e composições para o diagnóstico e tratamento de câncer BRPI1008566A8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15415909P	2009-02-20	2009-02-20
EP09002458A EP2221063A1 (en)	2009-02-20	2009-02-20	Methods and compositions for diagnosis and treatment of cancer
PCT/EP2010/001035 WO2010094490A1 (en)	2009-02-20	2010-02-18	Methods and compositions for diagnosis and treatment of cancer

Publications (2)

Publication Number	Publication Date
BRPI1008566A2 BRPI1008566A2 (pt)	2017-06-06
BRPI1008566A8 true BRPI1008566A8 (pt)	2018-01-02

Family

ID=40594202

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1008566A BRPI1008566A8 (pt)	2009-02-20	2010-02-18	métodos e composições para o diagnóstico e tratamento de câncer

Country Status (14)

Country	Link
US (1)	US9637548B2 (pt)
EP (3)	EP2221063A1 (pt)
JP (2)	JP5809067B2 (pt)
KR (1)	KR20110128315A (pt)
CN (1)	CN102325548A (pt)
AU (1)	AU2010215691B2 (pt)
BR (1)	BRPI1008566A8 (pt)
CA (1)	CA2750980A1 (pt)
IL (1)	IL214255B (pt)
MX (2)	MX349996B (pt)
NZ (2)	NZ601793A (pt)
SG (2)	SG10201402491YA (pt)
WO (1)	WO2010094490A1 (pt)
ZA (1)	ZA201105472B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1762575A1 (en)	2005-09-12	2007-03-14	Ganymed Pharmaceuticals AG	Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) *	2007-03-14	2008-09-17	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) *	2008-09-16	2010-03-24	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
AU2015255252B2 (en) *	2009-02-20	2017-11-23	BioNTech SE	Methods and compositions for diagnosis and treatment of cancer
US9809815B2 (en)	2009-02-20	2017-11-07	Ganymed Pharmaceuticals Ag	Methods and compositions for diagnosis and treatment of cancer
ES2988907T3 (es)	2009-11-11	2024-11-22	Astellas Pharma Inc	Anticuerpos específicos para claudina 6 (CLDN6)
EP2371864A1 (en)	2010-03-23	2011-10-05	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
EP2404936A1 (en)	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Cancer therapy using CLDN6 target-directed antibodies in vivo
NZ724296A (en)	2011-05-13	2020-05-29	Ganymed Pharmaceuticals Ag	Antibodies for treatment of cancer expressing claudin 6
EP2750694B8 (en) *	2011-08-08	2018-11-14	Curelab Oncology, Inc.	Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
ES2813415T3 (es)	2011-08-10	2021-03-23	Lankenau Inst Medical Res	Métodos y composiciones para el tratamiento de enfermedades autoinmunes e inflamatorias
EP2875046B2 (en)	2012-07-19	2025-04-30	Amgen Inc.	Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
KR101329655B1 (ko) *	2012-12-13	2013-11-14	강원대학교산학협력단	수압식 안마장치 및 그의 제어방법
JP2016512197A (ja) *	2013-03-05	2016-04-25	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール
RU2618628C1 (ru)	2013-04-17	2017-05-05	Пфайзер Инк.	Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний
GB201312133D0 (en) *	2013-07-05	2013-08-21	Univ Birmingham	Immunotherapy
WO2015014376A1 (en)	2013-07-31	2015-02-05	Biontech Ag	Diagnosis and therapy of cancer involving cancer stem cells
TWI819228B (zh) *	2013-08-05	2023-10-21	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
CN104634907B (zh) *	2013-11-11	2018-04-20	上海交通大学医学院附属瑞金医院	一类氨基酸分子组合作为胃癌标志物的用途
KR20200143672A (ko)	2018-02-02	2020-12-24	카르스젠 테라퓨틱스 컴퍼니, 리미티드	세포 면역 치료의 조합
WO2022048314A1 (zh) *	2020-09-03	2022-03-10	上海易慕峰生物科技有限公司	针对循环肿瘤细胞的免疫杀伤细胞在实体瘤治疗中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9019812D0 (en)	1990-09-11	1990-10-24	Scotgen Ltd	Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) *	1995-03-27	1998-11-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	T-cell receptors and their use in therapeutic and diagnostic methods
US5677139A (en)	1995-04-21	1997-10-14	President And Fellows Of Harvard College	In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5928631A (en)	1997-06-09	1999-07-27	The Procter & Gamble Company	Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20030166132A1 (en) *	1998-08-26	2003-09-04	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002536995A (ja) *	1999-02-22	2002-11-05	インサイト・ファーマスーティカルズ・インコーポレイテッド	結腸の疾患に関連する遺伝子
DK2796553T3 (da)	2000-03-30	2019-09-30	Whitehead Inst Biomedical Res	Rna-sekvensspecifikke formidlere af rna-interferens
KR20060125923A (ko) *	2001-06-20	2006-12-06	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
AT500651B9 (de) *	2003-05-27	2010-04-15	Altropus Gmbh	Aktiv immunisierender antikörper
US20080305493A1 (en)	2004-03-08	2008-12-11	Avalon Pharmaceuticals	Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods
EP2060583A1 (en) *	2007-10-23	2009-05-20	Ganymed Pharmaceuticals AG	Identification of tumor-associated markers for diagnosis and therapy
US20090258096A1 (en)	2008-04-11	2009-10-15	Bionovo, Inc.	Anticancer Methods Employing Extracts of Gleditsia sinensis Lam
US9809815B2 (en) *	2009-02-20	2017-11-07	Ganymed Pharmaceuticals Ag	Methods and compositions for diagnosis and treatment of cancer
EP2875046B2 (en)	2012-07-19	2025-04-30	Amgen Inc.	Human btnl3 proteins, nucleic acids, and antibodies and uses thereof

2009
- 2009-02-20 EP EP09002458A patent/EP2221063A1/en not_active Withdrawn
2010
- 2010-02-18 SG SG10201402491YA patent/SG10201402491YA/en unknown
- 2010-02-18 MX MX2015016088A patent/MX349996B/es unknown
- 2010-02-18 NZ NZ601793A patent/NZ601793A/xx unknown
- 2010-02-18 CA CA2750980A patent/CA2750980A1/en not_active Abandoned
- 2010-02-18 JP JP2011550479A patent/JP5809067B2/ja active Active
- 2010-02-18 KR KR1020117021992A patent/KR20110128315A/ko not_active Ceased
- 2010-02-18 SG SG2011051851A patent/SG173033A1/en unknown
- 2010-02-18 EP EP16202946.6A patent/EP3170511A1/en not_active Withdrawn
- 2010-02-18 US US13/201,726 patent/US9637548B2/en active Active
- 2010-02-18 BR BRPI1008566A patent/BRPI1008566A8/pt not_active IP Right Cessation
- 2010-02-18 WO PCT/EP2010/001035 patent/WO2010094490A1/en active Application Filing
- 2010-02-18 EP EP10705807A patent/EP2398497A1/en not_active Ceased
- 2010-02-18 NZ NZ594479A patent/NZ594479A/xx unknown
- 2010-02-18 CN CN2010800086568A patent/CN102325548A/zh active Pending
- 2010-02-18 AU AU2010215691A patent/AU2010215691B2/en active Active
- 2010-02-18 MX MX2011008429A patent/MX2011008429A/es unknown
2011
- 2011-07-24 IL IL214255A patent/IL214255B/en active IP Right Grant
- 2011-07-25 ZA ZA2011/05472A patent/ZA201105472B/en unknown
2015
- 2015-09-10 JP JP2015178261A patent/JP2016040253A/ja active Pending

Also Published As

Publication number	Publication date
MX2011008429A (es)	2011-09-29
US20110318264A1 (en)	2011-12-29
JP2012518608A (ja)	2012-08-16
AU2010215691B2 (en)	2015-09-03
KR20110128315A (ko)	2011-11-29
IL214255A0 (en)	2011-09-27
EP2221063A1 (en)	2010-08-25
NZ601793A (en)	2013-11-29
SG10201402491YA (en)	2014-07-30
NZ594479A (en)	2013-06-28
IL214255B (en)	2018-05-31
BRPI1008566A2 (pt)	2017-06-06
SG173033A1 (en)	2011-08-29
ZA201105472B (en)	2012-10-31
EP2398497A1 (en)	2011-12-28
WO2010094490A1 (en)	2010-08-26
CN102325548A (zh)	2012-01-18
US9637548B2 (en)	2017-05-02
MX349996B (es)	2017-08-23
JP2016040253A (ja)	2016-03-24
CA2750980A1 (en)	2010-08-26
JP5809067B2 (ja)	2015-11-10
EP3170511A1 (en)	2017-05-24
AU2010215691A1 (en)	2011-08-18

Publication	Publication Date	Title
BRPI1008566A8 (pt)	2018-01-02	métodos e composições para o diagnóstico e tratamento de câncer
BRPI1008564A2 (pt)	2018-02-27	métodos e composições para o dignóstico e tratamento de câncer
BRPI1007972A2 (pt)	2016-09-13	composições de combinação e métodos para o tratamento de câncer
BRPI0919238A2 (pt)	2019-09-24	métodos e composições para o tratamento de câncer
BR112012004979A2 (pt)	2015-09-08	composições para o tratamento de semente e métodos
BR112012005594A2 (pt)	2015-09-08	tratamento de câncer
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI0921321A2 (pt)	2018-10-16	métodos para o tratamento de indwcções e tumores
BRPI0909164A2 (pt)	2016-06-21	método e composições para o tratamento de câncer
BR112012018947A2 (pt)	2017-06-27	composição farmacêutica para tratamento e\ou prevenção do cancêr
BRPI0908026A2 (pt)	2015-07-21	Métodos para o tratamento de doenças do intestino
PT2367561E (pt)	2015-10-23	Composições e métodos para o tratamento da doença celíaca
BRPI0911112A2 (pt)	2015-10-06	composições e métodos para o tratamento do câncer de mama
BRPI1010874A2 (pt)	2017-05-30	composição para o tratamento de câncer de próstata
PT2512502T (pt)	2018-05-02	Métodos e composições para supressão de tumores
BRPI1007600A2 (pt)	2019-09-24	composições e métodos para tratamento de doenças cardiovasculares
BRPI1011325A2 (pt)	2016-03-15	composições e métodos para o tratamento de inflamação
EP2496244A4 (en)	2013-09-18	PHARMACORESISTANT IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
BRPI1007995A2 (pt)	2019-09-24	orto-aminoamidas para o tratamento de cãncer.
BRPI0922884A2 (pt)	2018-11-06	compostos para tratamento de câncer
BR112013011659A2 (pt)	2016-08-02	métodos de tratamento do câncer
BRPI0812932A2 (pt)	2014-12-09	Composições e métodos de tratar câncer
BRPI0922367A2 (pt)	2016-05-24	enzastaurin para o tratamento de câncer
BRPI0810207A2 (pt)	2014-10-14	Métodos e composições para o tratamento de câncer
BR112013028890A2 (pt)	2017-01-31	composições e métodos para o tratamento de câncer

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-12-11	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2019-04-02	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2501 DE 11-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.